Last reviewed · How we verify

Fecal filtrate transplantation

University of Pecs · Phase 3 active Biologic

Fecal filtrate transplantation is a Microbiome therapeutic / Fecal derivative Biologic drug developed by University of Pecs. It is currently in Phase 3 development for Clostridioides difficile infection (recurrent or refractory), Inflammatory bowel disease (Crohn's disease or ulcerative colitis).

Fecal filtrate transplantation restores beneficial microbial metabolites and immune-modulating compounds from healthy donor stool to rebalance the recipient's gut microbiome and intestinal barrier function.

Fecal filtrate transplantation restores beneficial microbial metabolites and immune-modulating compounds from healthy donor stool to rebalance the recipient's gut microbiome and intestinal barrier function. Used for Clostridioides difficile infection (recurrent or refractory), Inflammatory bowel disease (Crohn's disease or ulcerative colitis).

At a glance

Generic nameFecal filtrate transplantation
SponsorUniversity of Pecs
Drug classMicrobiome therapeutic / Fecal derivative
ModalityBiologic
Therapeutic areaGastroenterology / Immunology
PhasePhase 3

Mechanism of action

This therapeutic approach involves transferring filtered microbial byproducts and metabolites (rather than whole bacteria) from healthy donor feces to patients with dysbiotic conditions. The filtrate contains short-chain fatty acids, secondary bile acids, and other microbial metabolites that restore eubiotic conditions, strengthen intestinal epithelial tight junctions, and modulate local and systemic immune responses. By reconstituting the metabolic output of a healthy microbiome without transplanting live organisms, it aims to achieve therapeutic benefit with potentially reduced safety concerns compared to whole fecal microbiota transplantation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fecal filtrate transplantation

What is Fecal filtrate transplantation?

Fecal filtrate transplantation is a Microbiome therapeutic / Fecal derivative drug developed by University of Pecs, indicated for Clostridioides difficile infection (recurrent or refractory), Inflammatory bowel disease (Crohn's disease or ulcerative colitis).

How does Fecal filtrate transplantation work?

Fecal filtrate transplantation restores beneficial microbial metabolites and immune-modulating compounds from healthy donor stool to rebalance the recipient's gut microbiome and intestinal barrier function.

What is Fecal filtrate transplantation used for?

Fecal filtrate transplantation is indicated for Clostridioides difficile infection (recurrent or refractory), Inflammatory bowel disease (Crohn's disease or ulcerative colitis).

Who makes Fecal filtrate transplantation?

Fecal filtrate transplantation is developed by University of Pecs (see full University of Pecs pipeline at /company/university-of-pecs).

What drug class is Fecal filtrate transplantation in?

Fecal filtrate transplantation belongs to the Microbiome therapeutic / Fecal derivative class. See all Microbiome therapeutic / Fecal derivative drugs at /class/microbiome-therapeutic-fecal-derivative.

What development phase is Fecal filtrate transplantation in?

Fecal filtrate transplantation is in Phase 3.

What are the side effects of Fecal filtrate transplantation?

Common side effects of Fecal filtrate transplantation include Gastrointestinal symptoms (abdominal discomfort, bloating, diarrhea), Nausea, Fever.

Related